Pharmaceuticals, a company dedicated to developing a broad range of
novel central nervous system (CNS) therapies, today announced that the
company will present a comprehensive analysis of its recently completed
Phase 2b clinical trial of EVP-6124
in Alzheimer's disease at the Alzheimer's
Association International Conference 2012 (AAIC), being held July
14-19, 2012 in Vancouver, British Columbia. The data have been selected
for oral presentation as part of the conference's "Late Breaking Novel
Therapeutics" session, being held Wednesday, July 18, 2012 from 3:30 to
5 p.m. The data presentation will also be highlighted in an Alzheimer's
Association news briefing at the conference on Wednesday, July 18, 2012
from 7:30 to 8:30 a.m.
"These data mark an important step forward for EVP-6124 and the
development of EnVivo's broad pipeline of CNS therapies," said Kees
Been, president and chief executive officer of EnVivo Pharmaceuticals.
"We look forward to sharing the data analysis with our colleagues and
the scientific community at AAIC 2012."
EVP-6124 is a selective alpha-7 nicotinic agonist being studied in
patients with mild to moderate Alzheimer's disease. The Phase 2b
multi-center, dose ranging, placebo controlled, six-month study
took place in the U.S. and Europe and was designed to determine the
safety and efficacy of EVP-6124 in producing procognitive effects and
improving the clinical condition of Alzheimer's disease patients. The
primary endpoints of the trial were improvement in cognition as measured
by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog), a
commonly used and established outcome measure, and the CDR-SB, a
clinical rating scale that assesses patient function.